KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene

BACKGROUND: Triple-negative breast cancer (TNBC) is characterized by high rates of recurrence and poor overall survival. This is due, in part, to a deficiency of targeted therapies, making it essential to identify therapeutically targetable driver pathways of this disease. While epidermal growth fac...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberts, Melyssa S., Anstine, Lindsey J., Finke, Viviane S., Bryson, Benjamin L., Webb, Bryan M., Weber-Bonk, Kristen L., Seachrist, Darcie D., Majmudar, Parth R., Keri, Ruth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301986/
https://www.ncbi.nlm.nih.gov/pubmed/32552913
http://dx.doi.org/10.1186/s13058-020-01305-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301986/
https://www.ncbi.nlm.nih.gov/pubmed/32552913
http://dx.doi.org/10.1186/s13058-020-01305-7

Ejemplares similares